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Modified shock index - a strong predictor of 
outcome among patients presenting ST-segment 
elevation myocardial infarction
BACKGROUND
 In GUSTO trial, CS developed an average 12 h after enrolment into the study in STEMI
patients who were not considered to have CS at the time of initial assessment.3
 Although the increasing use of primary percutaneous coronary intervention (PPCI) in ST-
elevation myocardial infarction (STEMI) patients has contributed to reduce the incidence of
CS, it still occurs in 5–8% with approximately 50% mortality.2
 Cardiogenic shock (CS) remains the most common cause of death in ST-elevation
myocardial infarction (STEMI) patients.1
 Early identification of subclinical shock prevent the development of cardiogenic shock,
allowing a more assertive strategy and approach.
 The modified shock index (MAP) - ratio of heart rate to mean arterial pressure on
admission - has been shown in small studies to have a predictive value of mortality in
medical and trauma emergency patients. A value equal or superior to 1.3 was associated
to higher admissions on intensive unit care or death.4 To our Knowledge it was not tested
in STEMI patients.
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To evaluate the modified shock index, as a
predictor of in hospital and 6-month mortality
among patients (pts) admitted with STEMI.
PURPOSE
2389 pts admitted consecutively in 
our coronary care unit with ACS, 
from July of 2009 to June 2014
Pts with STEMI (n=1140)
Group 1
Pts with MSI <1.3 
n=1076, 94.4%
Group 2
Pts with MSI ≥1.3 
n=64, 5.6%
MSI = HR / MAP
Primary endpoint was the occurrence of death at 6 months.
METHODS
























MSI < 1.3 MSI ≥ 1.3
Age <60 years














MSI ≥ 1.3 P value
Age (years) 62±14 67±14 0.003
BMI < 19 kg/m2 (%) 0.9 1.6 NS






































ACS CABG PCI STROKE ATRIAL FIBRILLATION
MSI < 1.3
MSI ≥ 1.3
P=NS P=NS P=NS P=0.016 P=0.029
b. Previous Cardiovascular risk factors c. Previous Cardiovascular History
2. Clinical Presentation
MSI < 1.3 MSI ≥ 1.3 P value
SBP (mmHg) 129±27 93±19 <0.001
DBP (mmHg) 79±16 60±13 <0.001
MAP (mmHg) 96±18 71±14 <0.001
HR (BPM) 76±17 108±19 <0.001
Killip > 1 (%) 18.0 56.3 <0.001
Killip = 4 (%) 2.9 28.1 <0.001




Left Main disease or

























MSI < 1.3 MSI ≥ 1.3 P value
Aspirin (%) 99.1 99.8 NS
Clopidogrel (%) 99.1 98.4 NS
Beta Blockers (%) 86.7 62.5 <0.001
IIb IIIa glicoprotein inhibitors (%) 20.4 29.7 0.08
ACE-Inhibitors/RA blockers (%) 87.5 64.1 <0.001
Diuretics 32.0 58.7 <0.001
Statins (%) 98.7 91 0.001
LMWH (%) 32.5 34.4 NS
UFH (%) 72.7 78.1 NS
Inotropics (%) 7.4 50 <0.001
a. Pharmacological Treatment 
RESULTS
3. In-hospital Treatment
MSI < 1.3 MSI ≥ 1.3 P value
Revascularization (PPCI or CABG) 97.8 94.8 NS
Time door to balloon (h:min) 5 5h:15 NS
CABG 6.0 4.5 NS
Thrombolysis 1.1 0 NS
Non-invasive ventilation 2.5 21.7 <0.001
Mechanical ventilation 2.6 17.4 <0.001






















High Grade Heart Block
Mechanical Complications











































mortality 6.40 3.30 12.43 <0.001
30 days 
mortality 5.67 2.99 10.74 <0.001
6-month 




















5 1.02 1.09 0.004
eGFR < 60 
ml/min (CCG)
5.7
8 2.51 13.30 <0.001
KK > 1
1.7




7 0.83 2.94 NS
Anaemia
1.2
6 0.43 4.00 NS
Gender
1.0
0 0.56 2.23 NS
MSI≥ 1.3
3.8
1 1.81 8.03 <0.001
Log Rank P<0.001
Survival analysis by Kaplan-Meyer survival curves.
Independent Predictors of mortality, by Cox Regression.
RESULTS
 STEMI patients with high heart rate and low MAP are at risk of developing cardiogenic shock
and have a higher mortality.
 This is a single centre, retrospective study with all potential drawbacks of such design including unadjusted
data.
 We only have information on all-cause mortality and not cardiovascular mortality.
Limitations of study:
 MSI is an easily accessible tool, which can be used to signalize more critical patients.
 It can be used to prevent iatrogenic CS by avoiding some therapies in the early management of
high risk patients with relative hypotension and tachycardia.
 A large scale study should be performed to validate and compare it with current existing
validated indices.
 In our sample, MSI ≥ 1.3 was a strong predictor of in hospital and 6-month mortality among
patients with STEMI.
CONCLUSION
 By signaling patients with worse prognosis, it can help us to monitor them more closely.
